Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kwee Yong

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Ejhaem|January 27, 2025
Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in EnglandSally Moore, Laura Cornic, Christina-Jane Crossman-Barnes, et al.
Haematologica|February 29, 2020
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trialRakesh Popat, Dana Warcel, Jenny O'Nions, et al.
British Journal of Haematology|January 18, 2021
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patientsSarah Bird, Charlotte Pawlyn, Susanna Nallamilli, et al.
British Journal of Haematology|August 24, 2017
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis servicesRakesh Popat, Emma Dowling, Sufyan Achhala, et al.
British Journal of Haematology|February 23, 2024
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice PaperDaniel Hughes, Kwee Yong, Karthik Ramasamy, et al.
Annals of Hematology|October 28, 2014
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomideI-Jun Lau, Dean Smith, Robin Aitchison, et al.
British Journal of Haematology|November 24, 2018
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016Marc S Raab, Leah Fink, Paul Schoen, et al.
BMJ Open Quality|January 6, 2025
Real-world evaluation of physiotherapist-led exercise prehabilitation and rehabilitation during autologous stem cell transplantation in myeloma: a single-centre experienceJoanne Land, Michael K Luong, Alasdair Longden, et al.
British Journal of Haematology|July 9, 2002
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devicesMichael J Watts, Tim C P Somervaille, Stuart J Ings, et al.
BMC Cancer|July 13, 2016
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracingKaran Malhotra, Joseph S Butler, Hai Ming Yu, et al.
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Ejhaem|January 27, 2025
Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in EnglandSally Moore, Laura Cornic, Christina-Jane Crossman-Barnes, et al.
Haematologica|February 29, 2020
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trialRakesh Popat, Dana Warcel, Jenny O'Nions, et al.
British Journal of Haematology|January 18, 2021
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patientsSarah Bird, Charlotte Pawlyn, Susanna Nallamilli, et al.
British Journal of Haematology|August 24, 2017
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis servicesRakesh Popat, Emma Dowling, Sufyan Achhala, et al.
British Journal of Haematology|February 23, 2024
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice PaperDaniel Hughes, Kwee Yong, Karthik Ramasamy, et al.
Annals of Hematology|October 28, 2014
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomideI-Jun Lau, Dean Smith, Robin Aitchison, et al.
British Journal of Haematology|November 24, 2018
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016Marc S Raab, Leah Fink, Paul Schoen, et al.
BMJ Open Quality|January 6, 2025
Real-world evaluation of physiotherapist-led exercise prehabilitation and rehabilitation during autologous stem cell transplantation in myeloma: a single-centre experienceJoanne Land, Michael K Luong, Alasdair Longden, et al.
British Journal of Haematology|July 9, 2002
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devicesMichael J Watts, Tim C P Somervaille, Stuart J Ings, et al.
BMC Cancer|July 13, 2016
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracingKaran Malhotra, Joseph S Butler, Hai Ming Yu, et al.
Pageof 19